VOYA Investment Management’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-329,189
| Closed | -$33.6M | – | 2943 |
|
|
2023
Q2 | $33.6M | Buy |
329,189
+288,439
| +708% | +$27.3M | 0.03% | 410 |
|
|
2023
Q1 | $3.7M | Buy |
40,750
+21,290
| +109% | +$1.25M | ﹤0.01% | 1109 |
|
|
2022
Q4 | $739K | Hold |
19,460
| – | – | ﹤0.01% | 1804 |
|
|
2022
Q3 | $489K | Buy |
19,460
+8,835
| +83% | +$245K | ﹤0.01% | 2043 |
|
|
2022
Q2 | $323K | Hold |
10,625
| – | – | ﹤0.01% | 2126 |
|
|
2022
Q1 | $348K | Hold |
10,625
| – | – | ﹤0.01% | 2107 |
|
|
2021
Q4 | $280K | Sell |
10,625
-51
| -0.5% | -$3.95K | ﹤0.01% | 2339 |
|
|
2021
Q3 | $1.07M | Sell |
10,676
-119
| -1% | -$13.9K | ﹤0.01% | 1517 |
|
|
2021
Q2 | $1.53M | Buy |
10,795
+2,656
| +33% | +$300K | ﹤0.01% | 1347 |
|
|
2021
Q1 | $811K | Sell |
8,139
-32,786
| -80% | -$3.82M | ﹤0.01% | 1725 |
|
|
2020
Q4 | $5.06M | Sell |
40,925
-42,626
| -51% | -$5.6M | 0.01% | 812 |
|
|
2020
Q3 | $8.14M | Buy |
83,551
+31,405
| +60% | +$3.92M | 0.02% | 587 |
|
|
2020
Q2 | $8.14M | Sell |
52,146
-24,521
| -32% | -$3.73M | 0.02% | 596 |
|
|
2020
Q1 | $11.1M | Sell |
76,667
-15,380
| -17% | -$2.97M | 0.03% | 451 |
|
|
2019
Q4 | $18.8M | Buy |
92,047
+84,158
| +1,067% | +$15.4M | 0.04% | 398 |
|
|
2019
Q3 | $633K | Hold |
7,889
| – | – | ﹤0.01% | 1605 |
|
|
2019
Q2 | $744K | Buy |
7,889
+311
| +4% | +$26.9K | ﹤0.01% | 1527 |
|
|
2019
Q1 | $648K | Sell |
7,578
-143
| -2% | -$11.9K | ﹤0.01% | 1622 |
|
|
2018
Q4 | $433K | Buy |
7,721
+511
| +7% | +$31.2K | ﹤0.01% | 1817 |
|
|
2018
Q3 | $589K | Buy |
7,210
+1,114
| +18% | +$78.5K | ﹤0.01% | 1749 |
|
|
2018
Q2 | $213K | Buy |
+6,096
| New | +$186K | ﹤0.01% | 2333 |
|
Other funds holding RETA
VOYA Investment Management's RETA Position: Q3 2023 in Review
VOYA Investment Management sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2023, closing a stake of 329,189 shares — an estimated $33.6M sold.
VOYA Investment Management first reported a position in RETA in Q2 2018 and held it in 21 quarters. The position peaked at $33.6M in Q2 2023. 2 funds tracked by Wall St. Rank hold RETA as of Q3 2023.
- VOYA Investment Management reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
- VOYA Investment Management sold 329,189 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2023, an estimated $33.6M.
- VOYA Investment Management first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q2 2018 and held it in 21 quarters.
- VOYA Investment Management's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $33.6M in Q2 2023.
- 2 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2023.
Based on VOYA Investment Management's 13F filing for Q3 2023, filed 14 Nov 2023.